{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T02:23:36Z","timestamp":1772936616691,"version":"3.50.1"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Nelson\u2019s syndrome is considered a severe side effect that can occur after a total bilateral adrenalectomy in patients with Cushing\u2019s disease. It usually presents with clinical manifestations of an enlarging pituitary tumor including visual and cranial nerve alterations, and if not treated, can cause death through local brain compression or invasion. The first therapeutic option is surgery but in extreme cases of inaccessible or resistant aggressive pituitary tumors; the off-label use of chemotherapy with capecitabine and temozolomide can be considered. However, the use of this treatment is controversial due to adverse events, lack of complete response, and inability to predict results. We present the case of a 48-year-old man diagnosed with Nelson\u2019s syndrome with prolonged partial response and significant clinical benefit to treatment with capecitabine and temozolomide.<\/jats:p>","DOI":"10.3389\/fendo.2021.731631","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T08:37:05Z","timestamp":1636619825000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson\u2019s Syndrome: A Case Report"],"prefix":"10.3389","volume":"12","author":[{"given":"Oriol","family":"Mirallas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Filippi-Arriaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Hernandez Hernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"Aubanell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anas","family":"Chaachou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Garcia-Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Hernando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Mart\u00ednez-Saez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betina","family":"Biagetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaume","family":"Capdevila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1470","article-title":"Outcome of Bilateral Adrenalectomy in Cushing\u2019s Syndrome: A Systematic Review","volume":"98","author":"Ritzel","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1210\/er.2013-1048","article-title":"The Treatment of Cushing\u2019s Disease","volume":"36","author":"Pivonello","year":"2015","journal-title":"Endocr Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.1.117","article-title":"Incidence and Late Prognosis of Cushing\u2019s Syndrome: A Population-Based Study","volume":"86","author":"Lindholm","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3171\/foc.2007.23.3.15","article-title":"Nelson Syndrome: Comprehensive Review of Pathophysiology, Diagnosis, and Management","volume":"23","author":"Banasiak","year":"2007","journal-title":"Neurosurg Focus"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of Cushing\u2019s Syndrome: An Endocrine Society Clinical Practice Guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1530\/EJE-10-0466","article-title":"Nelson\u2019s Syndrome","volume":"163","author":"Barber","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1530\/EC-19-0065","article-title":"Peptide Receptor Radionuclide Therapy for Aggressive Pituitary Tumors: A Monocentric Experience","volume":"8","author":"Giuffrida","year":"2019","journal-title":"Endocr Connect"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0933","article-title":"Treatment of Aggressive Pituitary Tumours and Carcinomas: Results of a European Society of Endocrinology (ESE) Survey 2016","volume":"178","author":"McCormack","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1227\/NEU.0000000000000251","article-title":"High Response Rates and Prolonged Survival in Patients With Corticotroph Pituitary Tumors and Refractory Cushing Disease From Capecitabine and Temozolomide (CAPTEM): A Case Series","volume":"74","author":"Zacharia","year":"2014","journal-title":"Neurosurgery"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2015.01.038","article-title":"Nelson Syndrome: Update on Therapeutic Approaches","volume":"83","author":"Azad","year":"2015","journal-title":"World Neurosurg"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa649","article-title":"Approach to the Treatment of a Patient With an Aggressive Pituitary Tumor","volume":"105","author":"Lin","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-009-0211-1","article-title":"Temozolomide (Temodar\u00ae) and Capecitabine (Xeloda\u00ae) Treatment of an Aggressive Corticotroph Pituitary Tumor","volume":"14","author":"Thearle","year":"2011","journal-title":"Pituitary"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/nop\/npv059","article-title":"Temozolomide Treatment of Pituitary Carcinomas and Atypical Adenomas: Systematic Review of Case Reports","volume":"3","author":"Ji","year":"2016","journal-title":"Neurooncol Pract"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-015-1991-y","article-title":"Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas or Carcinomas","volume":"126","author":"Losa","year":"2016","journal-title":"J Neurooncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-020-09647-w","article-title":"Effects of CAPTEM (Capecitabine and Temozolomide) on a Corticotroph Carcinoma and an Aggressive Corticotroph Tumor","volume":"32","author":"Nakano-Tateno","year":"2020","journal-title":"Endocr Pathol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/2152-7806.96068","article-title":"Radiation Associated Tumors Following Therapeutic Cranial Radiation","volume":"3","author":"Chowdhary","year":"2012","journal-title":"Surg Neurol Int"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1100\/tsw.2010.210","article-title":"Temozolomide-Induced Shrinkage of a Pituitary Carcinoma Causing Cushing\u2019s Disease - Report of a Case and Literature Review","volume":"10","author":"Curt\u00f2","year":"2010","journal-title":"ScientificWorldJournal"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.731631\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T08:37:07Z","timestamp":1636619827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.731631\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,11]]},"references-count":17,"alternative-id":["10.3389\/fendo.2021.731631"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.731631","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,11]]},"article-number":"731631"}}